Last €0.38 EUR
Change Today -0.007 / -1.83%
Volume 3.8M
PHARM On Other Exchanges
Symbol
Exchange
EN Amsterdam
OTC US
Frankfurt
As of 11:35 AM 01/23/15 All times are local (Market data is delayed by at least 15 minutes).

pharming group nv (PHARM) Snapshot

Open
€0.38
Previous Close
€0.38
Day High
€0.39
Day Low
€0.37
52 Week High
02/18/14 - €0.73
52 Week Low
01/30/14 - €0.29
Market Cap
152.9M
Average Volume 10 Days
3.5M
EPS TTM
€-0.06
Shares Outstanding
407.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PHARMING GROUP NV (PHARM)

Related News

No related news articles were found.

pharming group nv (PHARM) Related Businessweek News

No Related Businessweek News Found

pharming group nv (PHARM) Details

Pharming Group N.V. develops, produces, and commercializes human therapeutic proteins for genetic disorders, and surgical and traumatic bleeding. Its technologies include transgenic platforms for the production of biopharmaceuticals, as well as technology and processes for the purification and formulation of biopharmaceuticals. The company offers Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor approved for the treatment of angioedema attacks in patients with hereditary angioedema in European Union countries, Norway, Iceland, and Liechtenstein. It is also involved in the development of rhC1INH for ischemia reperfusion injury (IRI) indications, including delayed graft function (kidney) and other IRI indications; rhFactor VIII for Haemophilia A; and hLactoferrin for nutritional applications. The company has a strategic collaboration with Shanghai Institute of Pharmaceutical Industry for the development, manufacture and commercialization of new products based on the Pharming technology platform. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

40 Employees
Last Reported Date: 04/30/14

pharming group nv (PHARM) Top Compensated Officers

Chief Executive Officer and Member of Managem...
Total Annual Compensation: €546.0K
Chief Operations Officer and Member of Manage...
Total Annual Compensation: €346.0K
Compensation as of Fiscal Year 2013.

pharming group nv (PHARM) Key Developments

Pharming Group NV and Salix Pharmaceuticals, Ltd. Announce Phase 2 Clinical Study of Ruconest

Pharming Group NV and Salix Pharmaceuticals Ltd. announced that the first patient was treated in their Phase 2 clinical study of Ruconest, (C1 Esterase Inhibitor Recombinant) 50 IU/kg, for prophylaxis in patients with hereditary angioedema (HAE). HAE patients deficient in C1 inhibitor and with a history of at least four attacks per month are being enrolled in the randomized, double-blind study, in which 30 patients will receive Ruconest either once or twice weekly, or placebo in each of 3 treatment periods. With the crossover design, all patients will receive each of the dosing regimens. The study will evaluate the safety and efficacy of Ruconest when used for prophylaxis of angioedema attacks in patients with HAE. The study will be conducted at sites in Canada, Europe, Israel, and the United States. The trial is being coordinated by principal investigators, Dr. Marco Cicardi, Professor at the University of Milan, and Dr. Marc Riedl, Associate Professor and Clinical Director of the US HAEA Angioedema Center at the University of California, San Diego.

Salix Pharmaceuticals Ltd. and Pharming Group NV Announce Launch of Hereditary Angioedema Drug in Us

Salix Pharmaceuticals Ltd. and Pharming Group NV announce the launch of RUCONEST 50IU/kg in the US for the treatment of acute angioedema attacks in adult and adolescent patients with hereditary angioedema, or HAE. Effectiveness in clinical studies was not established in HAE patients with laryngeal attacks. RUCONEST is available by prescription across the US through RUCONEST SOLUTIONS and comes with comprehensive patient support services. RUCONEST is manufactured by Pharming Group NV in the Netherlands. Salix has licensed exclusive rights from Pharming to commercialize RUCONEST in North America and market RUCONEST for the treatment of acute HAE attack symptoms.

Salix Pharmaceuticals, Ltd. and Pharming Group NV Announces the Launch of RUCONEST

Salix Pharmaceuticals Ltd. and Pharming Group NV announced the launch of RUCONEST 50 IU/kg in the United States for the treatment of acute angioedema attacks in adult and adolescent patients with hereditary angioedema (HAE). Effectiveness in clinical studies was not established in HAE patients with laryngeal attacks. RUCONEST, a recombinant C1 esterase inhibitor, can be administered by the patient after receiving training by a healthcare provider. RUCONEST is over 98% pure, and because it is not made from human plasma, it does not carry any known risk of passing on viruses that can be found in human blood. HAE is a rare genetic condition that affects between 1 in 10,000 to 1 in 50,000 people. It causes episodes of swelling in various parts of the body, including the hands, feet, abdomen and face. Patients with abdominal swelling often experience severe pain, nausea and vomiting. HAE attacks stem from a deficiency of the C1 inhibitor protein in the blood. The disease is often misdiagnosed, as the symptoms of an attack can mirror someone experiencing an allergic reaction. Severe, painful swelling can occur at any time, which means most people suffering from HAE deal with the constant fear of when their next attack might surface and how that might impair their lives and those around them. RUCONEST is available by prescription across the United States through RUCONEST SOLUTIONS and comes with comprehensive patient support services. RUCONEST is manufactured by Pharming Group NV in the Netherlands. Salix has licensed exclusive rights from Pharming to commercialize RUCONEST in North America and market RUCONEST for the treatment of acute HAE attack symptoms.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PHARM:NA €0.38 EUR -0.007

PHARM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €10.00 EUR +0.15
BioCryst Pharmaceuticals Inc $10.99 USD +0.29
Dyax Corp $15.51 USD -0.10
Oxford Biomedica PLC 7.68 GBp -0.35
Shire PLC 4,816 GBp +102.00
View Industry Companies
 

Industry Analysis

PHARM

Industry Average

Valuation PHARM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 28.7x
Price/Book 8.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 23.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMING GROUP NV, please visit www.pharming.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.